Serum levels of leptin in multiple myeloma patients and its relation to angiogenic and inflammatory cytokines

International Journal of Biological Markers

Volumn 19, Issue 1, 2004, Pages 52-57

  Alexandrakis, Michael G ^a   Passam, F H ^c   Sfiridaki, A ^d   Pappa, C A ^a   Moschandrea, J A ^b   Kandidaki, E ^d   Tsirakis, G ^a   Kyriakou, D S ^e  

^a UNIVERSITY OF CRETE   (Greece)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^c SOTIRIA GENERAL HOSPITAL   (Greece)

^d Venizelion General Hospital   (Greece)

^e UNIVERSITY HOSPITAL OF LARISSA   (Greece)

Author keywords

Angiogenesis; Inflammation; Leptin; Multiple myeloma

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; BETA 2 MICROGLOBULIN; BISPHOSPHONIC ACID DERIVATIVE; C REACTIVE PROTEIN; CYTOKINE; DEXAMETHASONE; DOXORUBICIN; INTERLEUKIN 1BETA; LEPTIN; MELPHALAN; PREDNISONE; VASCULOTROPIN; VINCRISTINE;

ADULT; ADVANCED CANCER; AGED; ANGIOGENESIS; ARTICLE; CANCER STAGING; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE SEVERITY; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; METABOLISM; MULTIPLE MYELOMA; ONCOLOGICAL PARAMETERS; PROTEIN BLOOD LEVEL;

EID: 1942518925     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2008.510     Document Type: Article

References (35)

1. Auerx J, Staels B. Leptin. Lancet 1998; 351: 737-42.
2. Fantuzzi G, Faggioni R. Leptin in the regulation of immunity, inflammation, and hematopoiesis. J Leukoc Biol 2000; 68: 437-46.
3. Ahima RS, Prabakaran D, Mantzoros C, et al. Role of leptin in the neuroendocrine response to fasting. Nature 1996; 382: 250-2.
4. Lord GM, Matarese G, Howard JK, Baker RJ, Bloom SR, Lechler RI. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature 1998; 394: 897-901.
5. Santos-Alvarez J, Goberna R, Sanchez-Margalet V. Human leptin stimulates proliferation and activation of human circulating monocytes. Cell Immunol 1999; 194: 6-11.
6. Tsuchiya T, Shimizu H, Horie T, Mori M. Expression of leptin receptor in lung: leptin as a growth factor. Eur J Pharmacol 1999; 365: 273-9.
7. Konopleva M, Mikhail A, Estrov Z, et al. Expression and function of leptin receptor isoforms in myeloid leukemia and myelodysplastic syndromes: proliferative and anti-apoptotic activities. Blood 1999; 93: 1668-76.
8. Faggioni R, Jones-Carson J, Reed D, et al. Leptin deficient (ob/ob) mice are protected from T cell-mediated hepatotoxicity: role of tumor necrosis factor-alpha and IL-118. Proc Natl Acad Sci USA 2000; 97: 2367-72.
9. Gainsford T, Wilson TA, Metcalf D, et al. Leptin can induce proliferation, differentiation and functional activation of hemopoietic cells. Proc Natl Acad Sci USA 1996; 93: 14564-8.
10. Bennett BD, Solar GP, Yuan JQ, Mathias J, Thomas GR, Matthews W. A role for leptin and its cognate receptor in hematopoiesis. Curr Biol 1996; 6: 1170-80.
11. Sierra-Honigmann MR, Nath AK, Murakami C, et al. Biological action of leptin as an angiogenic factor. Science 1998; 281: 1683-6.
12. Cao R, Brakenheim E, Wahlestedt C, Thyberg J, Cao Y. Leptin induces vascular permeability and synergistically stimulates angiogenesis with FGF-2 and VEGF. Proc Natl Acad Sci USA 2001; 98: 6390-5.
13. Park HY, Kwon HM, Lim HJ, et al. Potential role of leptin in angiogenesis: leptin,induces endothelial cell proliferation and expression of matrix metalloproteinases in vivo and in vitro. Exp Mol Med 2001; 33: 95-102.
14. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma. Cancer 1975; 36: 842-54.
15. Martin Bland. An introduction to medical statistics, 3rd ed. Oxford, UK: Oxford University Press 2000; 61.
16. Bruserud O, Huang TS, Glenjen N, Gjersten BT, Foss B. Leptin in human acute myelogenous leukemia: studies of in vivo levels and in vitro effects of native functional leukemia blasts. Haematologica 2002; 87: 584-95.
17. Gaja A, Chury Z, Pecen L, Frakova H, Jandakova E, Hejlova N. Bone marrow and peripheral blood leptin levels in lymphoproliferative diseases - relation to the bone marrow fat and infiltration. Neoplasma 2000; 47: 307-12.
18. Wex H, Ponelis E, Wex T, Dressedorfer R, Mittler U, Vorwek P. Plasma leptin and leptin receptor expression in childhood acute lymphoblastic leukemia. Int J Hematol 2002; 76: 446-52.
19. Fleet J. Leptin and bone: does the brain control bone biology? Nutr Rev 2000; 58: 209-11.
20. Dankbar B, Padro T, Leo R, et al. Vascular endothelial growth factor and interieukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 2000; 95: 2630-6.
21. Abilgaard N, Glerup H, Rungby J, et al. Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myeloma. Eur J Haematol 2000; 64: 121-9.
22. Bataille R, Chappard D, Klein B. The critical role of interleukin-6, interleukin 1- and macrophage colony stimulating factor in the pathogenesis of bone lesions in multiple myeloma. Int J Clin Lab Res 1992; 21: 283-7.
23. Akira S. IL-6 regulated transcription factors. Int J Biochem Cell Biol 1997; 29: 1401-18.
24. Mareel M, Leroy A. Clinical, cellular and molecular aspects of cancer invasion. Physiol Rev 2003; 83: 337-76.
25. Attoub S, Noe V, Pirola L, et al. Leptin promotes invasiveness of kidney and colonic epithelial cells via phosphoinositide 3-kinase-, Rho- and Rac-dependent signalling pathways. FASEB J 2000; 14: 2329-38.
26. Lust JA, Donovan KA. The role of interleukin-1 in the pathogenesis of multiple myeloma. Hematol Oncol Clin North Am 1999; 13: 1117-25
27. Costes V, Portier M, Lu ZY, Rossi JF, Bataille R, Klein B. Interleukin-1 in multiple myeloma: producer cells and their role in the control of IL-6 production. Br J Haematol 1998; 103: 1152-60.
28. Sezer O, Niemoller K, Eucker J, et al. Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma. Ann Hematology 2001; 79: 574-7.
29. Rajkumar SV, Leong T, Roche PC, et al. Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res 2000; 6: 3111-6.
30. Choi JH, Ahn MJ, Jang SJ, et al. Absence of clinical prognostic value of vascular endothelial growth factor and microvessel density in multiple myeloma. Int J Hematol 2002; 76: 460-4.
31. Iversen PO, Drevon CA, Reseland JE. Prevention of leptin binding to its receptor suppresses rat leukemic cell growth by inhibiting angiogenesis. Blood 2002; 100: 4123-8.
32. Iwasaki T, Hamano T, Ogata A, Hashimoto N, Kitano M, Kakishita E. Clinical significance of vascular endothelial growth factor and hepatocyte growth factor in multiple myeloma. Br J Haematol 2002; 116: 796-802.
33. Sezer O, Jakob C, Eucker J, et al. Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma. Eur J Haematol 2001; 66: 83-8.
34. Alexandrakis MG, Passam FH, Sfiridaki A, Kandidaki E, Roussou P, Kyriakou DS. Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity. Am J Hematol 2003; 72: 229-33.
35. Saad MF, Riad-Gabriel MG, Khan A, et al. Diurnal and ultradian rhythmicity of plasma leptin: effects of gender and adiposity. J Clin Endocrinol Metab 1998; 83: 453-9.